WednesdayGS

Bioassays for Bispecifics – Double the Trouble or Double the Fun?

Date
April 29, 2020
This product is not available for individual purchase, but it is available as part of the following products:

The structures and functions of modern biotherapeutics are becoming increasingly complex. A new generation of diverse multi-modal molecules has quickly emerged, where single molecules can bind multiple targets, harbor multiple activities, have combinatorial/synergistic activities, or all of the above. The complexity of multi-modal biotherapeutics brings about new challenges for bioassay development, as well as exciting opportunities for the application of novel assay formats and technologies.

Speakers

Speaker Image for Stephen Hartman
AbbVie Inc.
Speaker Image for David Cirelli
Pfizer, Inc.
Speaker Image for Li Liu
Pfizer, Inc.
Speaker Image for Ames Register
Genentech, a Member of the Roche Group
Speaker Image for Omar Tounekti
Health Canada

Related Products

Thumbnail for Bioassays for Cell and Gene Therapy
Bioassays for Cell and Gene Therapy
With increasing numbers of cell and gene therapy products in development and entering commercialization, more and more sponsors are facing a unique set of challenges of developing bioassays for cell and gene therapy products…
Thumbnail for Development of Homogeneous Dual-cell Based T-cell Dependent Cellular Cytotoxicity Assays
Development of Homogeneous Dual-cell Based T-cell Dependent Cellular Cytotoxicity Assays
Protein-based therapeutics have undergone an evolution since the first products were marketed over 30 years ago…